- Home
- SBAC vs BIIB Comparison
SBAC vs BIIB Comparison
Compare SBAC & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBAC
- BIIB
- Stock Information
- Founded
- SBAC 1989
- BIIB 1978
- Country
- SBAC United States
- BIIB United States
- Employees
- SBAC N/A
- BIIB N/A
- Industry
- SBAC Real Estate Investment Trusts
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- SBAC Real Estate
- BIIB Health Care
- Exchange
- SBAC Nasdaq
- BIIB Nasdaq
- Market Cap
- SBAC 24.0B
- BIIB 25.1B
- IPO Year
- SBAC 1999
- BIIB 1991
- Fundamental
- Price
- SBAC $202.10
- BIIB $149.34
- Analyst Decision
- SBAC Buy
- BIIB Buy
- Analyst Count
- SBAC 14
- BIIB 26
- Target Price
- SBAC $254.93
- BIIB $248.00
- AVG Volume (30 Days)
- SBAC 903.1K
- BIIB 1.6M
- Earning Date
- SBAC 02-24-2025
- BIIB 02-11-2025
- Dividend Yield
- SBAC 1.94%
- BIIB N/A
- EPS Growth
- SBAC 39.29
- BIIB 10.05
- EPS
- SBAC 6.34
- BIIB 11.06
- Revenue
- SBAC $2,660,958,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- SBAC N/A
- BIIB N/A
- Revenue Next Year
- SBAC $2.90
- BIIB N/A
- P/E Ratio
- SBAC $31.97
- BIIB $13.47
- Revenue Growth
- SBAC N/A
- BIIB N/A
- 52 Week Low
- SBAC $183.64
- BIIB $145.07
- 52 Week High
- SBAC $256.68
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- SBAC 29.93
- BIIB 31.81
- Support Level
- SBAC $197.16
- BIIB $145.07
- Resistance Level
- SBAC $204.58
- BIIB $149.92
- Average True Range (ATR)
- SBAC 4.27
- BIIB 3.57
- MACD
- SBAC -1.08
- BIIB 0.18
- Stochastic Oscillator
- SBAC 16.86
- BIIB 22.27
About SBAC SBA Communications Corporation
SBA Communications owns and operates almost 40,000 cell towers throughout North America, South America, and Africa. It leases space on its towers to wireless service providers, which install equipment on the towers to support their wireless networks. The company has a very concentrated customer base, with most revenue in each market being generated by just the top few mobile carriers. It owns more than 17,000 towers in the US, which accounted for about 70% of the company's total revenue in 2023. Internationally, SBA's greatest presence is in Brazil, where it operates roughly 10,000 towers. SBA operates as a real estate investment trust.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.